Stay updated with breaking news from Eric Benevich. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Rating) – Investment analysts at William Blair boosted their Q1 2023 earnings per share (EPS) estimates for Neurocrine Biosciences in a note issued to investors on Tuesday, April 18th. William Blair analyst M. Minter now expects that the company will post earnings of $0.71 per share for the quarter, […]
Neurocrine Biosciences (NASDAQ:NBIX – Get Rating) had its target price decreased by Wedbush from $131.00 to $128.00 in a research report sent to investors on Monday morning, Benzinga reports. Wedbush currently has an outperform rating on the stock. Wedbush also issued estimates for Neurocrine Biosciences’ Q1 2023 earnings at $0.71 EPS, Q4 2023 earnings at […]
Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Rating) have received an average recommendation of “Moderate Buy” from the twenty research firms that are covering the company, Marketbeat Ratings reports. Five investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating […]
Hanseatic Management Services Inc. bought a new stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Rating) in the fourth quarter, HoldingsChannel.com reports. The institutional investor bought 4,559 shares of the company’s stock, valued at approximately $545,000. Neurocrine Biosciences comprises approximately 1.4% of Hanseatic Management Services Inc.’s investment portfolio, making the stock its 16th […]
Canaccord Genuity Group upgraded shares of Neurocrine Biosciences (NASDAQ:NBIX – Get Rating) from a hold rating to a buy rating in a research report report published on Thursday morning, MarketBeat.com reports. Canaccord Genuity Group currently has $132.00 price target on the stock, up from their previous price target of $124.00. NBIX has been the subject […]